Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab

Leuk Lymphoma. 2007 Feb;48(2):431-3. doi: 10.1080/10428190601059704.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cyclophosphamide / therapeutic use
  • DNA, Viral / blood
  • DNA, Viral / genetics*
  • Doxorubicin / therapeutic use
  • Hepatitis B / blood
  • Hepatitis B / etiology*
  • Hepatitis B / genetics
  • Hepatitis B virus / genetics*
  • Hepatitis B virus / metabolism
  • Humans
  • Lymphoma, B-Cell / blood
  • Lymphoma, B-Cell / complications
  • Lymphoma, B-Cell / drug therapy*
  • Lymphoma, Large B-Cell, Diffuse / blood
  • Lymphoma, Large B-Cell, Diffuse / complications
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Male
  • Middle Aged
  • Prednisone / therapeutic use
  • Rituximab
  • Vincristine / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • DNA, Viral
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol